Lymphoplasmacytic Lymphoma Recruiting Phase 2 / 3 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0031072 (Lymphoplasmacytic Lymphoma)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04799275Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaTreatment